Background: Hydroxychloroquine (HCQ) treatment is frequently prescribed for coronavirus disease 2019 (COVID-19). Electrocardiographic (ECG) monitorization is recommended because HCQ causes QT interval prolongation. The index of cardioelectrophysiological balance (iCEB), calculated as the ratio of QT interval / QRS duration. In recent years, iCEB has been described as an important marker for dysrhthmias. Decreased or increased iCEB is related with lethal ventricular arrhythmias.
Aim of the study: In our research, we purposed to investigate the relationship between iCEB and HCQ in patients with COVID-19.
Methods: 200 patients (males, 84 ; females, 116 ; 60.4 ± 13.8 years) with PCR positive and chest tomography findings compatible with COVID-19 pneumonia were registered in the research. Demographic, clinical, and laboratory data for all patients were collected. ECG was recorded from all patients on admission to COVID-19 clinic, in oral treatment with HCQ (200 mg, twice daily) for at least 5 days. iCEB (QT/QRS) was calculated from the 12-lead electrocardiogram.
Results: The mean age of the patients was 60.4 ± 13.8 years. Compared to admission ECG, ECG on day 5 showed significant increases in heart rate, QT interval, corrected QT (QTc) interval, and iCEB.
Conclusions: Our results suggested that iCEB is related with HCQ treatment in patients with COVID-19. Previous studies have show that high iCEB is related with torsade de Pointes (TdP), ventricular tachycardia.
ECG Electrodiagnosis Hydroxychloroquine arrhythmia COVID-19.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar | |
Erken Görünüm Tarihi | 18 Mart 2022 |
Yayımlanma Tarihi | 18 Mart 2022 |
Gönderilme Tarihi | 22 Kasım 2021 |
Kabul Tarihi | 21 Ocak 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 39 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.